Ignacio Muñoz-Sanjuán, Cajal Neuroscience CEO
November 29, 2022 07:00 AM ESTUpdated 03:12 PM
Financing
Startups

Ca­jal Neu­ro­science launch­es with $96M Se­ries A, tack­ling Alzheimer's and Parkin­son's

Tyler Patchen

News Reporter

Ca­jal Neu­ro­science has emerged with a $96 mil­lion Se­ries A and plans to dis­cov­er drug can­di­dates in Alzheimer’s and Parkin­son’s with a wealth of gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times